Impact Stats Section

Our customers save time, cost and human resource when synthesis, screening and testing, with results up to:

0
Fewer compounds synthesised
0
Less potency screening
0
Less in vivo testing

Trusted by top biopharma companies

Thousands of med chemists from global drug discovery companies, including 50% of the top biopharma, trust StarDrop to accelerate time from hit to candidate.

Sanofi logo
Johnson & Johnson logo
UCB logo
BIAL logo
Apollo Therapeutics logo
Fundamental Pharma logo
Remedy Plan logo
Novalix logo
astronauTx logo
Arrakis logo
Captor logo
Sanofi logo
Johnson & Johnson logo
UCB logo
BIAL logo
Apollo Therapeutics logo
Fundamental Pharma logo
Remedy Plan logo
Novalix logo
astronauTx logo
Arrakis logo
Captor logo
Spacer

StarDrop case studies

Case Study Cards
Southern Research Institute

Improving anti-inflammation agents with StarDrop's predictive models

Read Case Study
adMare Bioinnovations

Supporting Canadian chemistry pioneers with fast SAR analysis

Read Case Study
Novalix

Accelerating early-stage drug discovery by connecting multidisciplinary teams

Read Case Study
Spacer

Cerella case studies

Partner Case Studies
Astra Zeneca

Translating in vitro data to in vivo savings

Read more
Genentech

76% reduction in assays required

Read more
MSD

Deep learning imputation for peptide bioactivity and property prediction

Read more
Takeda

700,000 compounds and 1,000 experimental endpoints

Read more
Spacer

BioPharmics case study

Featured Case Study

Book a demo with one of our scientists

Discover how Optibrium’s comprehensive in silico platform can boost the speed, efficiency, and productivity of your chemistry discovery programmes.

Five of the world’s top ten pharma and biotech companies trust Optibrium to power their discovery workflows.